Tucson pharmaceutical company sells exclusive option for cancer drug in deal worth up to $190 million | oneFAPvoice

welcome to oneFAPvoice

- a positively charged Familial Adenomatous Polyposis community.
  • join today!

Tucson pharmaceutical company sells exclusive option for cancer drug in deal worth up to $190 million


Sucampo unveiled Monday its agreement with Tuscon, Arizona-based Cancer Prevention Pharmaceuticals Inc. for the option to acquire an exclusive license to commercialize for a drug candidate in Phase III clinical trials. The therapy is aimed at treating a genetic condition called Familial Adenomatous Polyposis, or FAP, which can develop into colon cancer if it’s left untreated.

https://media-www.fapvoice.com/wp-content/uploads/2016/04/12.jpg

expertly curated content related to this topic